Genedrive

GDR · AIM · Health Care · mcap £18m · 1.1p

Beta Briefing, track record and bull & bear case are not ready for Genedrive yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 61 companies are already wired into a briefing: browse them.

David Nugent 10 Oct – 6 May · 9 notices

10.1% → 25.0%

share price at the notices 0.4–1.1p · now 1.1p 10 Oct 2025 29 Oct 2025 27 Jan 2026 3 Feb 2026 6 Feb 2026 24 Feb 2026 12 Mar 2026 6 May 2026

Robert English 24 Feb – 12 Mar · 2 notices

3.1% → 14.5%

share price at the notices 1.0–1.0p · now 1.1p 24 Feb 2026 12 Mar 2026

David Medlock 11 Mar · 1 notice

below 3% → 3.3%

share price at the notices 1.1p · now 1.1p 11 Mar 2026

On October 10 10 Oct · 1 notice

3.7% → 1.9%

share price at the notices 0.4p · now 1.1p 10 Oct 2025

Directors

other Genedrive plc announced board changes, with David Nugent joining as a Non-Executive Director and the company's largest shareholder, owning over 25% of issued share capital, who has waived his fee until the company is EBI 26 May 2026

other Genedrive plc announces that Dr. Ian Gilham has stepped down as Chairman and a Director, as previously indicated in the May 26, 2026 announcement. The company is actively recruiting for a new independent Non-Executive Ch 1 Jul 2026

purchase Genedrive plc announced that on August 28, 2026, Chief Executive Officer Dr. Gino Miele purchased 700,000 ordinary shares at 1.38p each, and Chief Financial Officer Russ Shaw acquired 700,000 ordinary shares at 1.40p eac 1 Sep 2026

Company filings. Not investment advice.